drugset
drugset / Trial / NCT07433673

Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)

NCT07433673 ↗

Phase 2 Recruiting 20 enrolled Columbia University Regeneron Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment

Summary

This study is being conducted to find out if treatment with gemcitabine, cisplatin, nab-paclitaxel, and cemiplimab can shrink previously inoperable tumors enough for surgery.

Timeline

Start
2026-08
Primary completion
2028-01
Completion
2029-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Cemiplimab Monoclonal antibody 300 mg Intravenous

Indications

colorectal cancer